Prediction Of Adverse Outcomes Following A Fragility Fracture
Funder
National Health and Medical Research Council
Funding Amount
$148,426.00
Summary
Individuals with an existing fracture are at increased risk of adverse outcomes such as re-fracture and premature mortality, but it is not clear why. We propose to evaluate risk factors, and prognostic models, for predicting the risk of adverse outcomes. We also propose to develop a quantitative risk-benefit framework for evaluating the clinical utility of such prognostic models and help ensure that therapies appropriately address real-life experience of osteoporotic patients.
Fractures And Bisphosphonates: Reviving Osteoporosis Treatment Uptake By Identifying The Genetic, Material, And Microstructural Risk Factors Of Atypical Femur Fractures.
Funder
National Health and Medical Research Council
Funding Amount
$1,053,094.00
Summary
Atypical femoral fractures (AFF) are uncommon, but catastrophic, complications of antiresorptive osteoporosis treatments including bisphosphonates. We will identify patients at risk of AFF by determining changes in their bone structure and quality, and identifying genes that increase the risk of these fractures. In this way, cheap and effective antiresorptive treatments can be targeted to patients at the lowest risk of AFF and alternative treatments to those at highest risk.
The ASPREE-fracture Sub-study: Does Daily Low-dose Aspirin Reduce Fracture Risk In Healthy Older Adults?
Funder
National Health and Medical Research Council
Funding Amount
$1,351,150.00
Summary
Disability, mortality and healthcare burden from fractures in older people is a growing problem worldwide. This is despite decades of clinical research, best practice guidelines and advances in therapies that aim to reduce fracture risk. The World Health Organization has identified fracture prevention as a public health priority. This study will determine whether a widely available, simple and inexpensive health intervention—aspirin—can reduce the incidence of fracture and associated disability ....Disability, mortality and healthcare burden from fractures in older people is a growing problem worldwide. This is despite decades of clinical research, best practice guidelines and advances in therapies that aim to reduce fracture risk. The World Health Organization has identified fracture prevention as a public health priority. This study will determine whether a widely available, simple and inexpensive health intervention—aspirin—can reduce the incidence of fracture and associated disability amongst older Australians.Read moreRead less
Economic Evaluation And Optimisation Of Services For The Preoperative Assessment And Management Of High Risk Surgical Patients
Funder
National Health and Medical Research Council
Funding Amount
$399,406.00
Summary
Medical co-morbidities in surgical patients affect post-surgical recovery, resulting in higher health service costs and poorer patient outcomes. Preliminary data indicate reduced post-surgical length of stay for patients with modifiable risk factors who attended a specialist preoperative clinic. This project will analyse existing data to identify patient sub-groups with the greatest capacity to benefit from specialist preoperative assessment, and evaluate new service pathways for these patients.
Osteoporosis is the commonest metabolic bone disease worldwide, and costs Australia >1% of GDP. It is a strongly inherited disease. We recently completed a genome-wide association study in 2000 postmenopausal women with either very high or very low bone density, and identified many genes contributing to BMD. The current study aims to use next-generation sequencing to study these women in greater genetic depth, aiming to identify more clearly the exact genetic determinants of bone mass.
Vitamin D, Bone Loss, Fracture And Mortality Outcome
Funder
National Health and Medical Research Council
Funding Amount
$408,736.00
Summary
Vitamin D most commonly from sunlight exposure is considered an important determinant of health, including the liability to falls and fractures; not only in the elderly but in adulthood in general. This study aims to distinguish if low vitamin D levels cause adverse health outcomes or relate to ill health, limited sunlight exposure and nutritional change. Only if low vitamin D level is causative of ill health does replacement make good public health sense.
Premature Mortality Post Fracture:A NSW Linked Data Study
Funder
National Health and Medical Research Council
Funding Amount
$391,012.00
Summary
Osteoporotic fractures are associated with increased morbidity and mortality. Anti-osteoporosis medications reduce re-fracture and possibly morality, yet osteoporosis is poorly treated. This study will link information from >260,000 people (45&Up study) with hospital admissions, medications and deaths to create the largest, detailed dataset of its kind. We will be able to determine cause of any fracture-associated mortality and the effect of medication to improve osteoporosis management.
This study will follow up a birth cohort for 25 years with the aim of looking at critical periods for bone development including the role of in utero exposures, early infancy, age 8 and age 16.
Fracture Associated Premature Mortality; An International Consortium
Funder
National Health and Medical Research Council
Funding Amount
$579,807.00
Summary
Following an osteoporotic fracture there is an increased premature mortality compared with someone who has not fractured. There is also evidence that anti-osteoporosis medication reduces this premature mortality. This study will determine the size of the fracture-mortality relationship and the effect of treatment on this mortality for different fracture types and in different populations by integrating data from multiple international epidemiology studies of osteoporosis.
Prevention And Treatment Of Bone Infection With CSA-90
Funder
National Health and Medical Research Council
Funding Amount
$350,983.00
Summary
Bone infections are a major challenge to treat, especially with the rise of drug resistant “superbugs”. We have access to a new agent, CSA-90, that has dual properties of being anti-microbial (antibiotic) and helps encourage bone growth. This project aims to expand upon our prior research and test CSA-90 for the treatment of chronic bone infections. We will also look at applying this technology to joint replacements and this drug may be particularly useful for coating orthopaedic implants.